You searched for "ICS"

536 results found

Lasers in benign prostatic hyperplasia

Clinical benign prostatic hyperplasia (BPH) impacts on the quality of life of many men. It is intimately related to ageing, but exact calculations of its prevalence remain difficult since an accurate clinical definition still eludes us. Histological BPH has been...

Priapism in sickle cell disease

What is sickle cell disease? Sickle cell disease (SCD) is one of the most common single-gene disorders in the UK affecting approximately one in every 2000 live births. Approximately 20-25 million people worldwide have SCD. It predominately affects those of...

Prostate cancer

Case 1 A 65-year-old man is referred to your two-week wait (2WW) clinic with a PSA of 7.0ng/mL. He has no lower urinary tract symptoms (LUTS), no past medical history, no family history of prostate cancer (PCa) and his performance...

Still Getting It Right First Time (GIRFT) in urology: meeting the challenges presented by COVID-19

Back in 2019, Simon Harrison – the then sole national lead for the urology workstream in the Getting It Right First Time (GIRFT) programme – wrote an article for Urology News on the GIRFT national report and how its recommendations...

New ultrasound imaging technique reliably spots prostate cancer, initial patient trial reveals

A groundbreaking new imaging approach developed by researchers at Heriot-Watt University has shown ‘extremely encouraging’ results in early-stage clinical trials on prostate cancer at the Western General Hospital in Edinburgh, Scotland. The ongoing clinical trial demonstrated an initial 94% sensitivity...

Prostate Cancer UK announced as official charity partner for MOBO Awards

The stage is set! Global dancehall queen Spice, UK rap kings Krept and Konan and the multi-talented Bashy are the first wave of performers announced to ignite the stage at the 2025 MOBO Awards.

Prostate Scotland’s COMPASS Impact Report highlights how men in Scotland are benefiting from prostate cancer support services

Prostate Scotland has published its COMPASS Impact Report 2020-2024, providing a detailed account of how its support services are improving outcomes for men living with prostate cancer across Scotland. Developed to complement care provided by clinical teams, COMPASS helps men...

Menopause in Aesthetics 2025

Menopause in Aesthetics (MiA) returns for its highly anticipated third year! After two groundbreaking events, MiA 2025 promises to push the boundaries of aesthetic medicine and menopause care. This ever-evolving conference and exhibition puts you at the forefront of one...

The Nurse Practitioner in Urology

This book is designed to meet the needs of nurse practitioners, advanced practice nurses and physician assistants working in urology in the US where Advanced Practice Certification, although not mandatory, is highly sought after by employers and service users alike....

The scent of Ethiopia: a personal story part 2

In May/June 2016 we featured a wonderful account of Zeeshan Aslam’s first trip with Urolink to the Hawassa Referral Hospital in Ethiopia (see here). One year on we are delighted that Zeeshan has once again taken the time to provide...

What is new in lasers for endourology: looking into the future

From the first cystoscopic argon and neodymium-YAG (yttrium-aluminium-garnet) laser used for bladder tumours in 1976 by Staehler et al. [1], lasers have proven to be a versatile and an evolving tool in the therapeutic management of a variety of urological...

Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...